Patents by Inventor Bruce A. Beutler
Bruce A. Beutler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20060257411Abstract: Compositions and methods are provided for screening and identifying compounds which modulate signaling of toll-like receptor 4 (TLR4) pathway via CD14 and a ligand. Methods are provided for treatment of various disease states such as inflammation or autoimmune disease in mammalian subjects by modulating toll-like receptor 4 (TLR4) pathway signaling via CD14 and a ligand. Transgenic non-human animals and methods for developing transgenic non-human animals are provided wherein the transgenic non-human animals comprise a loss-of-function mutation in the CD14 gene.Type: ApplicationFiled: May 4, 2006Publication date: November 16, 2006Inventors: Bruce Beutler, Zhengfan Jiang
-
Patent number: 7029861Abstract: The present invention describes a mutant TLR-4 in mice that does not recognize endotoxin and therefore does not stimulate the secretion of TNF from macrophages. Methods of detecting the mutation are provided; as are methods screening for drugs that may stimulate TNF production. Finally methods of incorporating and expressing the mutant TLR-4 genes into a host cell are contemplated.Type: GrantFiled: September 15, 1999Date of Patent: April 18, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Bruce A. Beutler, Alexander Poltorak
-
Patent number: 6046309Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: June 7, 1995Date of Patent: April 4, 2000Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 6019969Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: June 7, 1995Date of Patent: February 1, 2000Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 5989836Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: June 7, 1995Date of Patent: November 23, 1999Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 5925548Abstract: Engineered cell surface receptors are described that are constitutively active in the absence of the cytokine, hormone or molecule that normally activates the receptor. Receptors that constitutively signal are generally created by engineering the receptor to form multimers at the cell surface. Disclosed are various DNA, protein and cellular compositions and methods of making and using such constitutively active receptors. Particular examples are fusion proteins in which the stem, transmembrane domain and cytoplasmic domain are derived from a TNF receptor, and the extracellular, multimerizing domain is derived from an erythropoietin receptor. Transfection of such fusion protein constructs into cells is shown to result in a strong cytotoxic effect.Type: GrantFiled: December 9, 1996Date of Patent: July 20, 1999Assignee: Board of Regents, The University of Texas SystemInventors: Bruce A. Beutler, Flavia M. Bazzoni
-
Patent number: 5863535Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: June 7, 1995Date of Patent: January 26, 1999Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 5849873Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: June 7, 1995Date of Patent: December 15, 1998Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 5817763Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: June 7, 1995Date of Patent: October 6, 1998Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 5770402Abstract: Disclosed are novel nucleic acid and peptide compositions comprising a constitutively-expressed CC chemokine. Also disclosed are methods of use for MIP-1.gamma. amino acid sequences and the DNA segments which encode them in the stimulation of an immune response, the production of limited pyrexia, the treatment of proliferative cell disorders and T-cell mediated diseases, and the prophylaxis of bacterial sepsis in an animal.Type: GrantFiled: April 5, 1995Date of Patent: June 23, 1998Assignee: Board of Regents, The University of Texas SystemInventors: Bruce A. Beutler, Alexander N. Poltorak
-
Patent number: 5760186Abstract: Antibodies to an inflammatory cytokine are disclosed. The inflammatory cytokine has been isolated from cells that have been incubated with a stimulator material and comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: June 7, 1995Date of Patent: June 2, 1998Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 5741484Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: June 7, 1995Date of Patent: April 21, 1998Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 5628148Abstract: A guide pin and conical guide pin receptor for aligning a door relative to a door frame or other stable grounded device. The pin and receptor align the door from horizontal misalignment and radially throughout 360.degree. relative to the axis of the pin receptor. In aligning the door, interfitting elements on the door and door frame are aligned including such elements as comprise key actuated interlocking switch systems.Type: GrantFiled: July 8, 1994Date of Patent: May 13, 1997Inventor: Bruce Beutler
-
Patent number: 5616688Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.Type: GrantFiled: March 7, 1994Date of Patent: April 1, 1997Assignee: The Rockefeller UniversityInventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
-
Patent number: 5447851Abstract: The invention relates generally to DNA sequences encoding chimeric polypeptides comprising extracellular portions of cytokine receptor polypeptides attached to a sequence encoding portions of IgG polypeptides. The invention relates generally, as well, to DNA sequences encoding chimeric polypeptides comprising extracellular portions of cytokine receptor polypeptides attached through oligomers encoding specifically cleavable peptide linkers to a sequence encoding portions of IgG heavy chain polypeptides More specifically, the invention relates to a construction in which a cDNA sequence encoding the extracellular domain of the human 55 kD TNF receptor is attached through an oligomer encoding a thrombin-sensitive peptide linker to a sequence encoding the F.sub.c portion and hinge region of a mouse IgGl heavy chain.Type: GrantFiled: April 2, 1992Date of Patent: September 5, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Bruce A. Beutler, Karsten Peppel, David F. Crawford